SPOTLIGHT: Regeneron wins FDA approval


The FDA has approved Regeneron's Arcalyst for two rare inflammatory diseases. The ailments are known as cryopyrin-associated periodic syndromes, which can cause pain, fever and hearing loss. Some 300 people in the U.S. suffer from these conditions. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.